CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 144 enrolled
Drug / intervention
sunitinib +2 moredrug
Likely dose
sunitinib 37.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02264665
NCT02264665N/ACompleted
CompareCT.gov

AN OBSERVATIONAL REAL-WORLD STUDY OF THE SYSTEMIC TREATMENT OF WELL-DIFFERENTIATED, UNRESECTABLE OR METASTATIC, PROGRESSIVE PANCREATIC NEUROENDOCRINE TUMOURS (PNET): A STUDY OF MORBIDITY AND MORTALITY AT 2 YEARS

Pfizer·observational·Posted Oct 15, 2014·Updated Nov 13, 2023

In Brief

An observational study evaluating sunitinib, everolimus, and 1 other intervention for Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive. Completed, enrolled 144 participants across 35 sites.

Detailed Summary

A descriptive, prospective (partly retrospective), multisite, observational study conducted in France in adult patients treated for a well differentiated, unresectable or metastatic, pancreatic neuroendocrine tumor with disease progression.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Neuroendocrine Tumor, Well Differentiated and Progressive
CountriesFrance
CollaboratorsNovartis, Keyrus Biopharma

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 15, 2014
Enrollment StartMay 12, 2015
Primary CompletionNov 18, 2019
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 11.7 years ago

Interventions

sunitinibdrug

sunitinib 37.5mg/d orally

everolimusdrug

everolimus 10mg/d orally

chemotherapies recommended in francedrug

depends on the chemotherapy prescribed (IV)